Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isarna pan-TGF-beta antisense oligonucleotide
- Development stage
- Preclinical
- Lead developer
- Isarna Therapeutics
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous, Intravitreal, Intracameral
01
Overview
Isarna Therapeutics is developing a portfolio of locked nucleic acid (LNA)-modified antisense oligonucleotides designed to target the three isoforms of transforming growth factor-beta (TGF-β1, TGF-β2, and TGF-β3) for the treatment of various cancers. TGF-β signaling is a key driver of tumor progression, facilitating immune evasion, angiogenesis, and the epithelial-mesenchymal transition (EMT). By selectively targeting the messenger RNA of these isoforms, Isarna's oncology program aims to suppress the pro-tumorigenic effects of the TGF-β pathway. While the company's lead candidate, ISTH0036, is focused on ophthalmic indications, this pan-TGF-β oncology program represents a distinct effort to address solid tumors and other oncology indications through RNA-targeted modulation of the tumor microenvironment.
- Other names
- Isarna oncology programpan-TGF-beta antisense oligonucleotide
02
Targets
TGFB3 (Transforming growth factor beta 3)TGFB1 (Transforming growth factor Beta-1 proprotein)TGFB2 (Transforming growth factor beta 2)
Beyond the preview
Go deeper on Isarna pan-TGF-beta antisense oligonucleotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Isarna pan-TGF-beta antisense oligonucleotide.